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A B S T R A C T
Introduction: Levetiracetam (LEV) is a broad spectrum antiepileptic drug (AED) with a unique mechanism
of action. This retrospective audit explores outcomes in patients commenced on LEV monotherapy at the
Epilepsy Unit at the Western Inﬁrmary, Glasgow, Scotland from 1st January 2001 until 30th June 2009.
Methods: LEV monotherapy was started in 228 patients (89 men, 139 women, aged 12–81 years [median
28 years]). Of these, 161 (70.6%) had partial-onset seizures, 59 (25.9%) had idiopathic generalized
epilepsies (35 primary generalized tonic–clonic seizures [PGTCS], 20 juvenile myoclonic epilepsy, 4
juvenile absence epilepsy), and 8 (3.5%) had unclassiﬁed GTCS. Initial dosing was 250 mg twice daily for
2 weeks, followed by 500 mg twice daily. Patients were reviewed every 6–8 weeks. If required, the LEV
dose was titrated in 500 mg increments to a maximum tolerated or effective dose.
Results: In total, 112 (49.1%) patients remained seizure-free for 1 year on a median LEV dose of
1000 mg/day (range 500–3000 mg/day). Patients were more likely to achieve seizure freedom with LEV
as a ﬁrst monotherapy (81 of 149 [54.4%]), as opposed to switching from another AED (31 of 79 [39.2%];
p = 0.03). In this latter group, seizure freedom was more likely in those who switched after failing their
1st or 2nd AED (n = 39 of 64 [60.9%]), compared to later in the treatment schedule (n = 2 of 15 [13.3%];
p = 0.029). Patients reporting <5 seizures (70 of 118) prior to starting LEV were more likely to become
seizure-free than those with 5 seizures (42 of 110; p = 0.001). Thirty-six (15.8%) patients had a 50%
seizure reduction over 1 year; 43 (18.9%) were classiﬁed as having a <50% improvement, but elected to
continue on LEV. The drug was withdrawn in 37 (16.2%) patients (30 side effects, 7 lack of efﬁcacy).
Eighteen (7.9%) patients reported intolerable neuropsychiatric symptoms (7 aggression, 7 mood swings,
2 irritability, 2 depression). Other side effects leading to drug withdrawal included sedation (n = 5) and
lethargy (n = 4).
Conclusion: Seizure freedom was achieved in around half the patients on a median LEV dose of 1000 mg/
day. This was more likely to occur in those taking the drug as ﬁrst monotherapy, and in those with <5
pre-treatment seizures. Around 50% of those who discontinued LEV due to side effects developed
neuropsychiatric symptoms.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Levetiracetam (LEV) has been widely prescribed across Europe
as adjunctive treatment of partial-onset seizures, myoclonic
seizures and primary generalized tonic–clonic seizures (PGTCS)
since its licensing in 2000. The mechanisms of action of LEV appear
different from other antiepileptic drugs (AEDs), in that it is thought
to act through binding to synaptic vesicle protein 2A thereby
interfering with recycling of synaptic vesicles and hence neuro-
transmitter release.1
In 2006, licence extension allowed LEV to be used as
monotherapy for the treatment of partial-onset seizures. Place-
bo-controlled studies showed that LEV monotherapy was more* Corresponding author. Tel.: +44 141 211 2133; fax: +44 141 211 2072.
E-mail address: linda.stephen@ggc.scot.nhs.uk (L.J. Stephen).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.04.004effective than placebo against refractory partial-onset seizures in
patients who were switched to monotherapy after achieving 50%
seizure reduction with adjunctive LEV.2 Doses of 1000 mg,
2000 mg, and 3000 mg/day were as efﬁcacious as 400 mg,
800 mg, and 1200 mg/day of sustained-release carbamazepine
against partial or GTCS in a multicentre, randomized, double-blind
head-to-head trial.3
Although double-blind randomized controlled studies of AEDs
are important to establish the efﬁcacy and safety of treatment for
regulatory purposes, strict entry and dosing criteria limit the
amount of useful data that can be derived to facilitate decision
making in routine clinical practice. Pragmatic studies in clinical
practice are increasingly recognised to provide data which
complement information derived from regulatory trials.4,5 The
aim of this retrospective audit was to explore outcomes in patients
who were prescribed LEV as monotherapy at the Epilepsy Unit at
the Western Inﬁrmary, Glasgow, Scotland.vier Ltd. All rights reserved.
Fig. 1. Number (percentage) of patients taking levetiracetam as a ﬁrst monotherapy
or who switched to the drug, who remained seizure-free for 1 year, optimally
controlled (50% or <50% seizure reduction for 1 year compared with baseline), or
who discontinued levetiracetam.
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Retrospective analysis of the computerised Epilepsy Unit
database identiﬁed 228 patients (89 men, 139 women, aged 12–
81 years [median 28 years]) who were prescribed LEV mono-
therapy between 1st January 2001 and 30th June 2009. Of the 228,
161 (70.6%) had focal-onset seizures, 59 (25.9%) had idiopathic
generalized epilepsies (35 PGTCS, 20 juvenile myoclonic epilepsy
[JME], 4 juvenile absence epilepsy [JAE]), and 8 (3.5%) had
unclassiﬁed GTCS. LEV was taken as a ﬁrst AED in 149 (65.4%)
who had newly diagnosed epilepsy. The remaining 79 (34.6%)
patients already established on AED treatment were switched to
LEV because of lack of efﬁcacy (n = 28) or side effects (n = 51) with
their previous AED. Overall, the number of seizures prior to starting
LEV was 1–30 (median 3); for newly treated patients this was 1–30
(median 3); for switched patients, 1–20 (median 2).
LEV was prescribed initially as 250 mg twice daily for 2 weeks,
increasing to 500 mg twice daily for most patients. Some patients
who became seizure-free or had very few seizures on 250 mg twice
daily elected to remain on this dose. Thereafter, if required, dosing
was adjusted as clinically indicated in 500 mg increments. The
optimal maintenance dose was identiﬁed for each patient according
to efﬁcacy and tolerability. As do all patients attending the Epilepsy
Unit, patients and/or care givers kept a written record of seizure
frequency prior to the addition of and during treatment with LEV.
Where possible, patients were reviewed by the same clinician every
6–8 weeks, or sooner if required. Clinical data were recorded in a
structured casesheet and entered into a computerised database.
Four primary end-points were established—seizure freedom for
at least 1 year on a given dose of LEV, 50% reduction (responder)
in seizure frequency over a 12-month period compared with 3-
month baseline on the highest tolerated dose of LEV, <50% seizure
frequency reduction (marginal effect) over 1 year compared with
baseline in patients wishing to continue LEV treatment, or
withdrawal of LEV due to lack of efﬁcacy, side effects, or both.
The x2 test was used for comparisons of categoric data. All
statistical tests were two-tailed. Calculations were computed
using Minitab for Windows (Release 13.32) software.
3. Results
Of the 228 patients taking LEV monotherapy, 112 (49.1%)
remained seizure-free for 1 year (Table 1). Seizure freedom was
achieved in 46.6% (75 of 161) of patients with partial-onset
seizures, 54.2% (32 of 59) of patients with idiopathic generalized
epilepsies (20 PGTCS, 10 JME, 2 JAE), and 62.5% (5 of 8) of patientsTable 1
Levetiracetam (LEV) monotherapy outcomes over 1 year in patients with different seiz
Seizure type/syndrome Treatment status Seizure-free 50% seizure
Partial-onset seizures Newly treated 54 17 
Switched 21 13 
Total 75 30 
PGTCS Newly treated 17 1 
Switched 3 1 
Total 20 2 
JME Newly treated 7 0 
Switched 3 3 
Total 10 3 
JAE Newly treated 0 0 
Switched 2 0 
Total 2 0 
Unclassiﬁed GTCS Newly treated 3 2 
Switched 2 0 
Total 5 2 
Total (%) 112 (49.1) 37 (16.2) 
PGTCS, primary generalized tonic–clonic seizures; JME, juvenile myoclonic epilepsy; JAwith unclassiﬁed GTCS. Median duration of treatment was 12
months (range 12–36 months). The median LEV dose in seizure-
free patients was 1000 mg/day (range 500–3000 mg/day). Patients
were more likely to achieve seizure freedom with LEV as a ﬁrst
monotherapy (81 of 149 [54.4%]), as opposed to switching from
another AED (31 of 79 [39.2%]; p = 0.03) (Fig. 1). In those who
switched, seizure freedom was more likely when the switch was
made after failing a 1st or 2nd AED (n = 39 of 64 [60.9%]), compared
to later in the treatment schedule (n = 2 of 15 [13.3%]; p = 0.029)
(Fig. 2). Patients with <5 seizures prior to the introduction of LEV
were more likely to become seizure-free (70 of 118 [59.3%])
compared to those with 5 seizures (42 of 110 [38.2%]; p = 0.001)
(Fig. 3).
A 50% seizure reduction was achieved in 36 (15.8%) patients,
and 43 (18.9%) had a <50% reduction over 12 months, but elected
to continue LEV monotherapy. In patients who switched to LEV,
outcomes were not signiﬁcantly different in the 28 who switched
due to lack of efﬁcacy (13 [46.4%] seizure-free, 5 [17.9%] 50%
seizure reduction, 7 [25%] <50% seizure reduction, 3 [10.7%]
discontinued LEV) compared to the 51 who switched because of
side effects with a previous AED (20 [39.2%] seizure-free, 7 [13.8%]
50% seizure reduction, 12 [23.5%] <50% seizure reduction, 12
[23.5%] discontinued LEV). Seven patients with learning disabil-
ities, all with partial-onset seizures, were started on LEV
monotherapy (median dose 1000 mg/day, range 500–2000 mg/
day). Of these, 4 were commenced on the drug as their ﬁrst
treatment, and 3 were switched to LEV. Five became seizure-free,
and 2 had a 50% reduction in seizures.ure types and syndromes.
 reduction <50% seizure reduction LEV withdrawal Total (%)
20 19 110
7 10 51
27 29 161 (70.6)
3 1 22
8 1 13
11 2 35 (15.3)
3 2 12
1 1 8
4 3 20 (8.8)
0 0 0
0 2 4
0 2 4 (1.8)
0 0 5
1 0 3
1 0 8 (3.5)
43 (18.9) 36 (15.8) 228 (100)
E, juvenile absence epilepsy; GTCS, generalized tonic–clonic seizures.
Fig. 2. Number (percentage) of patients switched to levetiracetam as a ﬁrst or
second substitute versus those switched as a 3rd substitute who remained
seizure-free for 1 year, or had optimal control/levetiracetam withdrawal.
Fig. 3. Outcomes with levetiracetam monotherapy in patients with <5 seizures
compared to those with 5 seizures prior to starting treatment.
Fig. 4. Final daily levetiracetam doses in different outcome groups.
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LEV was withdrawn in 37 (16.2%) patients (30 [13.1%] side effects,
7 [3.1%] lack of efﬁcacy). Side effects leading to withdrawal are
listed in Table 2. Neuropsychiatric symptoms (7 aggression, 7
mood swings, 2 irritability, 2 depression) led to LEV discontinua-
tion in 18 (7.9%) patients. Other reasons for discontinuation
included sedation (n = 5) and lethargy (n = 4). LEV dosing varied
widely in all four outcome groups, from seizure freedom on 500 mg
daily to withdrawal on 3000 mg daily (Fig. 4).
4. Discussion
Of the 228 patients taking LEV monotherapy, 49.1% remained
seizure-free for 1 year. This is a little lower than that found in the
randomized, controlled study comparing LEV monotherapy with
sustained release carbamazepine where 56.6% of patients ran-Table 2












a Some patients reported more than one side effect.domized to receive LEV were seizure-free for 1 year.3 However,
apart from marked differences in methodologies, the randomized
trial was performed in patients with newly diagnosed epilepsy
only, and this audit studied patients with new-onset and already
treated seizures. When analysis was performed on newly
diagnosed patients only, the seizure-free percentage rose to
54.4%, which was almost identical to that in the regulatory trial.
Not surprisingly, the percentage of patients achieving seizure
freedom on switching to LEV from another AED was much lower at
39.2%.6
Patients with a variety of seizure types and syndromes
beneﬁtted from LEV monotherapy. Of the 161 with focal-onset
seizures, 46.6% became seizure-free. This is a similar percentage
compared with other retrospective analyses. Six (46.2%) of 13
patients with partial-onset seizures who were commenced on LEV
had no seizures over a 6-month period.7 Of 46 adults with partial-
onset seizures, 17 (36.9%) remained seizure-free at 1 year having
switched to, or started LEV monotherapy de novo.8 LEV mono-
therapy resulted in 8 of 14 (57.1%) elderly patients with focal-onset
seizures gaining complete seizure control over 6 months.9 A
prospective, observational study found that 72% of 25 patients
with Alzheimer’s disease became seizure-free for at least 1 year
with the AED.10 A prospective, randomized parallel-group case–
control study of 95 patients with Alzheimer’s disease taking LEV
(n = 38), phenobarbital (n = 28), or lamotrigine (n = 29) over 13
months found no difference in efﬁcacy between the 3 AEDs (29%
LEV, 29% phenobarbital, 24% lamotrigine seizure-free).11 LEV was
associated with fewer adverse events and improved cognitive
performance.
The median LEV dose in seizure-free patients was 1000 mg/day
(range 500–3000 mg/day). LEV dosing varied widely in all four
outcome groups. In a responder-selected monotherapy study,
seizure-free patients took 3000 mg daily of the AED.2 When LEV
monotherapy was compared with controlled release carbamaze-
pine, seizure freedom was achieved with 1000–3000 mg/day with
86% of responders taking just 1000 mg LEV per day, mirroring the
results from this audit.3 Other monotherapy audits have reported
complete seizure control with 1000–2000 mg/day10 and 2000–
5000 mg/day.7,8 Patients with <5 seizures prior to the introduction
of LEV were more likely to become seizure-free compared to those
with 5 seizures. A high number of pre-treatment seizures have
been shown previously to be a poor prognostic indicator.12–14
Of the 7 patients with learning disabilities started on LEV
monotherapy, 5 became seizure-free and 2 had a 50% reduction
in seizure activity. There are no published monotherapy data with
which to compare these results. In a prospective multicentre open-
label study in 42 patients with epilepsy and learning disabilities,
adjunctive LEV reduced median seizure frequency from 4.3 per
week to 2.2 per week over 6 months.15 A Glasgow audit of
outcomes with adjunctive LEV in 156 patients with learning
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least 6 months, with 33 (21%) having a 50% reduction in
seizure frequency for 6 months, compared with baseline.16 Of
the seizure-free patients, 25 (63%) took 1000 mg or less of the
drug.
LEV was withdrawn in 15.7% of patients, the majority of whom
developed intolerable side effects on a wide range of doses.
Aggression and mood swings were the commonest symptoms
leading to drug withdrawal. Around 50% of patients who
discontinued LEV because of side effects did so due to neuropsy-
chiatric symptoms (aggression, mood swings, irritability, depres-
sion). Other side effects comprised sedation, lethargy, nausea,
vomiting, ataxia and dizziness. These are in keeping with
symptoms reported in the LEV arm of the multicentre randomized
trial comparing the monotherapy with sustained-release carba-
mazepine.3
5. Conclusion
This retrospective audit has shown that treatment with LEV
monotherapy resulted in around half of patients remaining
seizure-free for at least 1 year on a median dose of 1000 mg/day.
The drug was effective across a range of seizure types and
syndromes. Seizure freedom was more likely in those who had
had <5 pre-treatment seizures, compared to those with 5
seizures, and in those taking the drug as a ﬁrst monotherapy, as
opposed to those switched from another AED. Commonest
side effects leading to drug withdrawal included aggression,
mood swings, irritability, and depression, which are similar
to those reported in patients treated with adjunctive
LEV.17–20
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